[GILD] Enrolling GT1 patients in the Sofo/Riba study is bizarre. You don't drop clean, synergistic drugs like [GS-5885] you add them. You don't seek out longer durations with less potent combinations. Why not longer durations of Sofo/5885 in GT1? Why not study GT2 patients? Couldn't longer durations in GT2 help boost SVR rates within this genotype?
Not saying I think that is likely, but if you deny that's not at least some possibility, I think you're being naïve
Everything is possible. As of naive, well, if you think GILD would insert portion of a trial, which is so important to them that potentially threatens their HCV franchise which is why I used the word "doomed", into a ph3b trial that is conducted entirely in Russian, then you don't understand how biotech/pharma companies like GILD make decisions.
GILD certainly could have problem with sofosbuvir/5885 combo down the road. This isn't the clue they are sending.
Market Data 
Markets 
AI
